Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics

Journal of Medicinal Chemistry

Volumn 45, Issue 23, 2002, Pages 4984-4994

  Schmiedeberg, Niko ^a   Schmitt, Manfred ^b   Rölz, Christian ^a   Truffault, Vincent ^a   Sukopp, Martin ^a   Bürgle, Markus ^c   Wilhelm, Olaf G ^c   Schmalix, Wolfgang ^c   Magdolen, Viktor ^b   Kessler, Horst ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Wilex Biotechnology GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE RECEPTOR;

ARTICLE; BLOOD SAMPLING; CARBOXY TERMINAL SEQUENCE; CELL MIGRATION; CYTOFLUOROMETRY; DRUG RECEPTOR BINDING; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; HYDROPHOBICITY; PROTEIN DOMAIN; STRUCTURE ANALYSIS; SYNTHESIS; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CELL LINE; DRUG STABILITY; FLOW CYTOMETRY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR CONFORMATION; MOLECULAR MIMICRY; MOLECULAR STRUCTURE; PEPTIDES, CYCLIC; RECEPTORS, CELL SURFACE; SOLUTIONS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; URINARY PLASMINOGEN ACTIVATOR;

EID: 0037038308     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020254q     Document Type: Article

References (46)

1. Edwards, D. R.; Murphy, G. Proteases - Invasion and more. Nature 1998, 394, 527-528.
2. Johnsen, M.; Lund, L. R.; Rømer, J.; Almholt, K.; Danø, K. Cancer invasion and tissue remodeling: Common themes in proteolytic matrix degradation. Curr. Opin. Cell Biol. 1998, 10, 667-671.
3. Koblinski, J. E.; Ahram, M.; Sloane, B. F. Unraveling the role of proteases in cancer. Clin. Chim. Acta 2000, 291, 113-135.
4. Andreasen, P. A.; Egelund, R.; Petersen, H. H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci. 2000, 57, 25-40.
5. Foekens, J. A.; Peters, H. A.; Look, M. P.; Portengen, H.; Schmitt, M.; Kramer, M. D.; Brünner, N.; Jänicke, F.; Gelder, M. E. M.v.; Henzen-Logmans, S. C.; Putten, W. L. J. V.; Klijn, J. G. M. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 2000, 60, 636-643 and references therein.
6. Schmitt, M.; Wilhelm, O. G.; Reuning, U.; Krüger, A.; Harbeck, N.; Lengyel, E.; Graeff, H.; Gänsbacher, B.; Kessler, H.; Bürgle, M.; Stürzebecher, J.; Sperl, S.; Magdolen, V. The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis Proteolysis 2000, 14, 114-132.
7. Mazar, A. P. The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer. Anti-Cancer Drugs 2001, 12, 387-400.
8. Muehlenweg, B.; Sperl, S.; Magdolen, V.; Schmitt, M.; Harbeck, N. Interference with the urokinase plasminogen activator (uPA) system: A promising therapy concept for solid tumors. Exp. Opin. Biol. Ther. 2001, 1, 683-691.
9. Appella, E.; Robinson, E. A.; Ullrich, S. J.; Stoppelli, M. P.; Corti, A.; Cassani, G.; Blasi, F. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J. Biol. Chem. 1987, 262, 4437-4440.
10. Magdolen, V.; Rettenberger, P.; Koppitz, M.; Goretzki, L.; Kessler, H.; Weidle, U. H.; König, B.; Graeff, H.; Schmitt, M.; Wilhelm, O. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator. Eur. J. Biochem. 1996, 237, 743-751.
11. Bürgle, M.; Koppitz, M.; Riemer, C.; Kessler, H.; König, B.; Weidle, U. H.; Kellermann, J.; Lottspeich, F.; Graeff, H.; Schmitt, M.; Goretzki, L.; Reuning, U.; Wilhelm, O. G.; Magdolen, V. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides. Biol. Chem. 1997, 378, 231-237.
12. 19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87). Biol. Chem. 2001, 382, 1197-1205.
13. Kessler, H. Conformation and biological activity of cyclic peptides. Angew. Chem., Int. Ed. 1982, 21, 512-523.
14. Hansen, A. P.; Petros, A. M.; Meadows, R. P.; Nettesheim, D. G.; Mazar, A. P.; Olejniczak, E. T.; Xu, R. X.; Pederson, T. M.; Henkin, J.; Fesik, S. W. Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator. Biochemistry 1994, 33, 4847-4864.
15. Goodson, R. J.; Doyle, M. V.; Kaufman, S. E.; Rosenberg, S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 7129-7133.
16. Guo, Y.; Higazi, A. A.; Arakelian, A.; Sachais, B. S.; Cines, D.; Goldfarb, R. H.; Jones, T. R.; Kwaan, H.; Mazar, A. P.; Rabbani, S. A. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J. 2000, 14, 1400-1410.
17. Ploug, M.; Ostergaard, S.; Gårdsvoll, H.; Kovalski, K.; Holst-Hansen, C.; Holm, A.; Ossowski, L.; Danø, K. Peptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 2001, 40, 12157-12168.
18. Fong, S.; Doyle, M. V.; Goodson, R. J.; Drummond, R. J.; Stratton, J. R.; McGuire, L.; Doyle, L. V.; Chapman, H. A.; Rosenberg, S. Random peptide bacteriophage display as a probe for urokinase receptor ligands. Biol. Chem. 2002, 383, 149-158.
19. 15N "random coil" chemical shifts. J. Am. Chem. Soc. 1994, 116, 8466-8469.
20. 1H chemical shifts obtained as a function of temperature and trifluoroethanol concentration for the peptide series GGXGG. J. Biomol. NMR 1995, 5, 14-24.
21. Nilges, M.; Clore, G. M.; Gronenborn, A. M. Determination of three-dimensional structures of proteins from interproton distance data by dynamical simulated annealing from a random array of atoms. Circumventing problems associated with folding. FEBS Lett. 1988, 239, 129-136.
22. Mueller, G.; Gurrath, M.; Kurz, M.; Kessler, H. βVI turns in peptides and proteins: A model peptide mimicry. Proteins: Struct., Funct., Genet. 1993, 15, 235-251.
23. Richardson, J. S. The anatomy and taxonomy of protein structure. Adv. Protein Chem. 1981, 34, 167-339.
24. Lewis, P. N.; Momany, F. A.; Scheraga, H. A. Chain reversals in proteins. Biochim. Biophys. Acta 1973, 303, 211-229.
25. Rees, D. C.; Lewis, M.; Lipscomb, W. N. Refined crystal structure of carboxypeptidase A at 1.54 Å resolution. J. Mol. Biol. 1983, 168, 367-387.
26. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J. B.; Meyer, E. F., Jr.; Brice, M. D.; Rodgers, R. D.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The Protein Data Bank: A computer-based archival file for macromolecular structures. J. Mol. Biol. 1977, 112, 535-542.
27. Levitt, M. Conformational preferences of amino acids in globular proteins. Biochemistry 1978, 17, 4277-4285.
28. Gray, T. M.; Matthews, B. W. Intrahelical hydrogen bonding of serine, threonine and cysteine residues within α-helixes and its relevance to membrane-bound proteins. J. Mol. Biol. 1984, 175, 75-81.
29. Thornton, J. M.; Sibanda, B. L.; Edwards, M. S.; Barlow, D. J. Analysis, design and modification of loop regions in proteins. BioEssays 1988, 8, 63-69.
30. Wilmot, C. M.; Thornton, J. M. Analysis and prediction of the different types of β-turn in proteins. J. Mol. Biol. 1988, 203, 221-232.
31. Hutchinson, E. G.; Thornton, J. M. A revised set of potentials for β-turn formation in proteins. Protein Sci. 1994, 3, 2207-2216.
32. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.
33. Ploug, M.; Ostergaard, S.; Hansen, L. B. L.; Holm, A.; Danø, K. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation. Biochemistry 1998, 37, 3612-3622.
34. Zee-Cheng, K.-Y.; Cheng, C.-C. Experimental antileukemic agents. Preparation and structure-activity study of S-tritylcysteine and related compounds. J. Med. Chem. 1970, 13, 414-418.
35. Carpino, L. A.; Han, G. Y. 9-Fluorenylmethoxycarbonyl amino-protecting group. J. Org. Chem. 1972, 37, 3404-3409.
36. Fields, G. B.; Noble, R. L. Solid-phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 1990, 35, 161-214.
37. Wüthrich, K.; Billeter, M.; Braun, W. Pseudostructures for the 20 common amino acids for use in studies of protein conformations by measurements of intramolecular proton-proton distance constraints with nuclear magnetic resonance. J. Mol. Biol. 1983, 169, 949-961.
38. Kim, Y.; Prestegard, J. H. Measurement ofvicinal couplings from cross-peaks in COSY spectra. J. Magn. Reson. 1989, 84, 9-13.
39. Torda, A. E.; Scheek, R. M.; van Gunsteren, W. F. Time-dependent distance restraints in molecular dynamics simulations. Chem. Phys. Lett. 1989, 157, 289-294.
40. Torda, A. E.; Scheek, R. M.; van Gunsteren, W. F. Time averaged NOE distance restraints applied to tendamista. J. Mol. Biol. 1990, 214, 223-230.
41. Pearlman, D. A.; Kollman, P. A. Are time-averaged restraints necessary for nuclear magnetic resonance refinement? A model study for DNA. J. Mol. Biol. 1991, 220, 457-479.
42. Nanzer, A. P.; van Gunsteren, W. F.; Torda, A. E. Parametrisation of time-averaged distance restraints in MD simulations. J. Biomol. NMR 1995, 6, 313-320.
43. Guthaus, E.; Bürgle, M.; Schmiedeberg, N.; Hocke, S.; Eickler, A.; Kramer, M. D.; Sweep, C. G. J.; Magdolen, V.; Kessler, H.; Schmitt, M. uPA-Silica-Particles (SP-uPA): A novel analytical system to investigate uPA-uPAR-interaction and to test synthetic uPAR-antagonists as potential cancer therapeutics. Biol. Chem. 2002, 383, 207-216.
44. Kobayashi, H.; Schmitt, M.; Goretzki, L.; Chucholowski, N.; Calvete, J.; Kramer, M.; Günzler, W. A.; Jänicke, F.; Graeff, H. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J. Biol. Chem. 1991, 266, 5147-5152.
45. Brünner, N.; Thompson, E. W.; Spang-Thomsen, M.; Rygaard, J.; Danø, K.; Zwiebel, J. A. IacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis. Eur. J. Cancer 1992, 28A, 1989-1995.
46. Fischer, K.; Lutz, V.; Wilhelm, O.; Schmitt, M.; Graeff, H.; Heiss, P.; Nishiguchi, T.; Harbeck, N.; Kessler, H.; Luther, T.; Magdolen, V.; Reuning, U. Urokinase induces proliferation of human ovarian carcinoma cells: Characterization of structural elements required for growth factor function. FEBS Lett. 1998, 438, 101-105.